ChemicalBook > Product Catalog >API >Circulatory system drugs >Antiarrhythmics Drugs >Propafenone

Propafenone

Propafenone Structure
CAS No.
54063-53-5
Chemical Name:
Propafenone
Synonyms
C07381;WZ-884-643;WZ-884-642;PROPAFENONE;AKOS 215-08;Propafenonum;Propafenone-d;Propafenone USP;(RS)-Propafenone;5-OH-Propafenone-D5
CBNumber:
CB2183169
Molecular Formula:
C21H27NO3
Molecular Weight:
341.44
MOL File:
54063-53-5.mol
Modify Date:
2024/3/19 15:37:50

Propafenone Properties

Boiling point 519.6±50.0 °C(Predicted)
Density 1.096±0.06 g/cm3(Predicted)
storage temp. 2-8°C
solubility DMSO: 68 mg/mL (199.16 mM);Ethanol: 41 mg/mL (120.08 mM)
form Solid
pka pKa 9.27 (Uncertain)
color White to Off-White
Water Solubility 759.9ug/L(22.5 ºC)
CAS DataBase Reference 54063-53-5(CAS DataBase Reference)
NIST Chemistry Reference Propafenone(54063-53-5)

SAFETY

Risk and Safety Statements

Symbol(GHS) 
GHS07
Signal word  Warning
Hazard statements  H302-H315-H319-H335
Precautionary statements  P261-P280-P301+P312-P302+P352-P305+P351+P338
Hazard Codes  T
Risk Statements  46-22
Safety Statements  53-36/37/39-45
WGK Germany  3
RTECS  UH2833000

Propafenone Chemical Properties,Uses,Production

Uses

Cardiac depressant (anti-arrhythmic).

Definition

ChEBI: An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydroch oride salt in the management of supraventricular and ventricular arrhythmias.

World Health Organization (WHO)

Propafenone, a membrane-stabilizing antiarrhythmic agent, was introduced into medicine in the mid 1980s. Shortly afterwards, its use became associated with cases of severe cardiac arrhythmias, which led to notable restrictions in the drug's indications in at least two countries. See also WHO comment for flecainide.

General Description

Propafenone, 2-[2'-hydroxy-3-(propylamino)propoxy]-3-phenylpropiophenone (Rythmol), a classIC antiarrhythmic drug, contains a chiral center and is marketedas the racemic mixture. Therapy with the racemicmixture of propafenone produces effects that can be attributedto both (S) and (R) enantiomers. Although (R) and (S)enantiomers exert similarNa+channel–blocking effects, the(S) enantiomer also produces aβ-adrenergic blockade. As aresult, the (S) enantiomer is reported to be 40-fold morepotent than the (R) enantiomer as an antiarrhythmic agent.The enantiomers also display stereoselective dispositioncharacteristics. The (R) enantiomer is cleared more quickly.Hepatic metabolism is polymorphic and determined genetically.Ten percent of Caucasians have a reduced capacity tohydroxylate the drug to form 5-hydroxypropafenone. Thispolymorphic metabolism accounts for the interindividualvariability in the relationships between dose and concentrationand, thus, variability in the pharmacodynamic effects ofthe drug. The 5-hydroxy metabolites of both enantiomersare as potent as the parent compound in blocking Na+channels.Propafenone also depresses the slow inward current ofCa2+ions.

Clinical Use

Propafenone has been used for acute termination orlong-term suppression of ventricular arrhythmias. It isbound in excess of 95% to 1-acid glycoprotein in theplasma. It is absorbed effectively, but bioavailability is estimatedto be less than 20% because of first-pass metabolism.Less than 1% is eliminated as unchanged drug. Therapywith propafenone may produce effects that can be attributedto both (S) and (R) enantiomers. Thus, the effects may bemodulated because of an enantiomer–enantiomer interactionwhen patients are treated with the racemate.

Side effects

Concurrent administration of propafenone with digoxin, warfarin, propranolol, or metoprolol increases the serum concentrations of the latter four drugs. Cimetidine slightly increases the propafenone serum concentrations. Additive pharmacological effects can occur when lidocaine, procainamide, and quinidine are combined with propafenone.
As with other members of class IC, propafenone may interact in an unfavorable way with other agents that depress A-V nodal function, intraventricular conduction, or myocardial contractility. Overall, 21 to 32% of patients have adverse effects. The most common are dizziness or light-headedness, metallic taste, nausea, and vomiting; the most serious are proarrhythmic events.

Precautions

Propafenone is contraindicated in the presence of severe or uncontrolled congestive heart failure; cardiogenic shock; sinoatrial, A-V, and intraventricular disorders of conduction; and sinus node dysfunction, such as sick sinus syndrome. Other contraindications include severe bradycardia, hypotension, obstructive pulmonary disease, and hepatic and renal failure. Because of its weak β-blocking action, propafenone may cause possible dose-related bronchospasm.This problem is greatest in patients who are slow metabolizers.

Propafenone Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 123)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
J S LABS +91-7330612784 +91-7330612784 Tamil Nadu, India 160 58 Inquiry
Humble Healthcare Limited +91-9720093000 +91-8006400378 Uttar Pradesh, India 141 58 Inquiry
Mylan Laboratories Ltd +91-4023550543 +91-4030866666 Telangana, India 150 58 Inquiry
Medilink Pharmachem +91 (79) 3007-0133 New Delhi, India 424 50 Inquiry
CLEARSYNTH LABS LTD. +91-22-45045900 Hyderabad, India 6351 58 Inquiry
Pharmaffiliates Analytics and Synthetics P. Ltd +91-172-5066494 Haryana, India 6773 58 Inquiry
Sykem Pharma Resarch And Development 08066085844Ext 735 Maharashtra, India 20 58 Inquiry
Capot Chemical Co.,Ltd. 571-85586718 +8613336195806 China 29798 60 Inquiry
career henan chemical co +86-0371-86658258 +8613203830695 China 29897 58 Inquiry
Chongqing Chemdad Co., Ltd +86-023-6139-8061 +86-86-13650506873 China 39916 58 Inquiry
WZ-884-643 β-Phenyl-2'-[3-(propylamino)-2-hydroxypropoxy]propiophenone C07381 5-OH-Propafenone-D5 N-(carboxypheny)guanidine hydrochloride 1-(2-(2-Hydroxy-3-(propylamino) -3-phenylpropan-1-one 1-(2-(2-hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanone 1-[2-(2-hydroxy-3-propylamino-propoxy)phenyl]-3-phenyl-propan-1-one AKOS 215-08 PROPAFENONE 1-(2-(2-hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanon (RS)-Propafenone 1-Propanone, 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenyl- (9CI) Propafenone USP Propafenone (base and/or unspecified salts) PROPAFENONE HCL USP 2'-[2-Hydroxy-3-(propylamino)propoxy]-β-phenylpropiophenone WZ-884-642 Propafenonum Propafenone USP/EP/BP PropafenoneQ: What is Propafenone Q: What is the CAS Number of Propafenone Q: What is the storage condition of Propafenone Q: What are the applications of Propafenone 1-[2-[2-oxo-3-(propylamino)propoxy]phenyl]-3-phenyl-1-propanone Propafenone-d 54063-53-5 C21H27N03HCl C21H27NO3 Cell Signaling and Neuroscience Cell Biology BioChemical Other Sodium Channel Modulators Monovalent Ion Channels Ion Channels Sodium Channel Modulators Voltage-gated Ion Channels Propafenone API Isotopically Labeled Pharmaceutical Reference Standard Metabolite Reference Standard